These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26517216)

  • 41. Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia.
    Biundo R; Weis L; Facchini S; Formento-Dojot P; Vallelunga A; Pilleri M; Antonini A
    Parkinsonism Relat Disord; 2014 Apr; 20(4):394-9. PubMed ID: 24495708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic accuracy of the Thai version of the Mini-Addenbrooke's Cognitive Examination as a mild cognitive impairment and dementia screening test.
    Charernboon T
    Psychogeriatrics; 2019 Jul; 19(4):340-344. PubMed ID: 30699469
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reliability, validity, and diagnostic accuracy of Parkinson's Disease-Cognitive Rating Scale in Iranian patients with idiopathic Parkinson's disease.
    Mahmoudi Asl A; Mehdizadeh M; Kulisevsky J; Sabet A; Taghavi Azar Sharabiani P; Mehdizadeh H; Ashayeri H; Taghizadeh G
    Disabil Rehabil; 2022 May; 44(10):2091-2098. PubMed ID: 32924645
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The clinical utility of naturalistic action test in differentiating mild cognitive impairment from early dementia in memory clinic.
    Bruce I; Ntlholang O; Crosby L; Cunningham C; Lawlor B
    Int J Geriatr Psychiatry; 2016 Mar; 31(3):309-15. PubMed ID: 26264127
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The validity of the Addenbrooke's Cognitive Examination-Revised (ACE-R) in acute stroke.
    Morris K; Hacker V; Lincoln NB
    Disabil Rehabil; 2012; 34(3):189-95. PubMed ID: 21954948
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The MoCA: well-suited screen for cognitive impairment in Parkinson disease.
    Dalrymple-Alford JC; MacAskill MR; Nakas CT; Livingston L; Graham C; Crucian GP; Melzer TR; Kirwan J; Keenan R; Wells S; Porter RJ; Watts R; Anderson TJ
    Neurology; 2010 Nov; 75(19):1717-25. PubMed ID: 21060094
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anosognosia for cognitive and behavioral symptoms in Parkinson's disease with mild dementia and mild cognitive impairment: Frequency and neuropsychological/neuropsychiatric correlates.
    Orfei MD; Assogna F; Pellicano C; Pontieri FE; Caltagirone C; Pierantozzi M; Stefani A; Spalletta G
    Parkinsonism Relat Disord; 2018 Sep; 54():62-67. PubMed ID: 29709507
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Validation of the Montreal Cognitive Assessment (MoCA) in Spanish as a screening tool for mild cognitive impairment and mild dementia in patients over 65 years old in Bogotá, Colombia.
    Gil L; Ruiz de Sánchez C; Gil F; Romero SJ; Pretelt Burgos F
    Int J Geriatr Psychiatry; 2015 Jun; 30(6):655-62. PubMed ID: 25320026
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical predictors of cognitive impairment and psychiatric complications in Parkinson's disease.
    Campos LS; Guimarães RP; Piovesana LG; Azevedo PC; Santos LM; D'Abreu A
    Arq Neuropsiquiatr; 2015 May; 73(5):390-5. PubMed ID: 26017203
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease.
    van Steenoven I; Aarsland D; Hurtig H; Chen-Plotkin A; Duda JE; Rick J; Chahine LM; Dahodwala N; Trojanowski JQ; Roalf DR; Moberg PJ; Weintraub D
    Mov Disord; 2014 Dec; 29(14):1809-15. PubMed ID: 25381961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Measuring functional impact of cognitive impairment: validation of the Parkinson's disease cognitive functional rating scale.
    Kulisevsky J; Fernández de Bobadilla R; Pagonabarraga J; Martínez-Horta S; Campolongo A; García-Sánchez C; Pascual-Sedano B; Ribosa-Nogué R; Villa-Bonomo C
    Parkinsonism Relat Disord; 2013 Sep; 19(9):812-7. PubMed ID: 23773412
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia.
    Barton B; Grabli D; Bernard B; Czernecki V; Goldman JG; Stebbins G; Dubois B; Goetz CG
    Mov Disord; 2012 Feb; 27(2):248-53. PubMed ID: 22162144
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rapid communication: Preliminary validation of a telephone adapted Montreal Cognitive Assessment for the identification of mild cognitive impairment in Parkinson's disease.
    Benge JF; Kiselica AM
    Clin Neuropsychol; 2021 Jan; 35(1):133-147. PubMed ID: 32779959
    [No Abstract]   [Full Text] [Related]  

  • 54. Diagnostic utility of Montreal Cognitive Assessment in the Fifth Edition of Diagnostic and Statistical Manual of Mental Disorders: major and mild neurocognitive disorders.
    Liew TM; Feng L; Gao Q; Ng TP; Yap P
    J Am Med Dir Assoc; 2015 Feb; 16(2):144-8. PubMed ID: 25282632
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment.
    Kulisevsky J; Pagonabarraga J
    Mov Disord; 2009 Jun; 24(8):1103-10. PubMed ID: 19353727
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cognitive Function and Quality of Life in Parkinson's Disease: A Cross-Sectional Study.
    Tang Y; Liang X; Han L; Peng F; Shen B; Yu H; Shen Y; Shen C; Yu J; Wang J
    J Parkinsons Dis; 2020; 10(3):1209-1216. PubMed ID: 32568115
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An analysis of the cognitive items of the movement disorders society checklist for the diagnosis of dementia in patients with Parkinson's disease.
    Oliveira GN; Souza CP; Foss MP; Tumas V
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1260-3. PubMed ID: 26289825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extended "Timed Up and Go" assessment as a clinical indicator of cognitive state in Parkinson's disease.
    Evans T; Jefferson A; Byrnes M; Walters S; Ghosh S; Mastaglia FL; Power B; Anderton RS
    J Neurol Sci; 2017 Apr; 375():86-91. PubMed ID: 28320196
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of the Montreal Cognitive Assessment and Alzheimer's Disease-8 as cognitive screening measures in Parkinson's disease.
    Brown DS; Bernstein IH; McClintock SM; Munro Cullum C; Dewey RB; Husain M; Lacritz LH
    Int J Geriatr Psychiatry; 2016 Mar; 31(3):264-72. PubMed ID: 26177715
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
    Almuqbel M; Melzer TR; Myall DJ; MacAskill MR; Pitcher TL; Livingston L; Wood KL; Keenan RJ; Dalrymple-Alford JC; Anderson TJ
    Parkinsonism Relat Disord; 2016 Jan; 22():54-61. PubMed ID: 26627939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.